Moreover, the TR-FRET technology could be extended to the quantification of other proteins of interest, such as p95HER2, the relevance of which as a prognostic marker has recently been reported in patients with HER2-positive breast cancer treated with trastuzumab.47,48. The gene discussed is ERBB2; the disease is breast carcinoma.